p. 127−132
2090-7125
Vol.63/No.1
p. 133−137
2090-7125
Vol.63/No.1
p. 138−142
2090-7125
Vol.63/No.1
p. 143−156
2090-7125
Vol.63/No.1
p. 157−171
2090-7125
Vol.63/No.1
p. 172−184
2090-7125
Vol.63/No.1
p. 185−194
2090-7125
Vol.63/No.1
p. 195−205
2090-7125
Vol.63/No.1
0.05), where the serum activity of MMP2 in healthy subjects was 0.14±0.03 ng/ml and in patients with NSCLC was 0.09±0.03 % and the serum activity of MMP9 in healthy subjects was 0.13±0.019 ng/ml and in patients with NSCLC was 0.10±0.03 %.
Conclusions: Our results indicated that the circulating levels of Endostatin, and TIMP-1 in patients with NSCLC may be valuable future tools for treatment planning and monitoring of treatment, however, these blood tests need to be standardized and validated in large-scale prospective clinical trials.
]]>
p. 206−209
2090-7125
Vol.63/No.1
p. 210−212
2090-7125
Vol.63/No.1
p. 213−216
2090-7125
Vol.63/No.1
p. 217−228
2090-7125
Vol.63/No.1
p. 238−247
2090-7125
Vol.63/No.1
p. 248−257
2090-7125
Vol.63/No.1